11/21
07:00 am
imab
I-Mab to Participate at the Piper Sandler Healthcare Conference
Medium
Report
I-Mab to Participate at the Piper Sandler Healthcare Conference
11/15
08:04 am
imab
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
11/14
07:09 am
imab
I-Mab Reports Third Quarter 2024 Results [Yahoo! Finance]
Low
Report
I-Mab Reports Third Quarter 2024 Results [Yahoo! Finance]
11/14
07:00 am
imab
I-Mab Reports Third Quarter 2024 Results
Low
Report
I-Mab Reports Third Quarter 2024 Results
11/6
07:00 am
imab
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
Medium
Report
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
10/31
07:00 am
imab
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
Medium
Report
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
10/30
07:00 am
imab
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
Medium
Report
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
10/28
07:00 am
imab
I-Mab to Participate at the Truist Securities BioPharma Symposium
Low
Report
I-Mab to Participate at the Truist Securities BioPharma Symposium
9/17
08:02 am
imab
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
9/16
04:03 pm
imab
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 [Yahoo! Finance]
Medium
Report
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 [Yahoo! Finance]
9/16
04:01 pm
imab
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
Medium
Report
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
9/10
07:00 am
imab
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
Low
Report
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
8/29
08:42 am
imab
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
8/28
12:31 pm
imab
I-MAB (IMAB) Q2 2024 Earnings Call Transcript [Seeking Alpha]
Medium
Report
I-MAB (IMAB) Q2 2024 Earnings Call Transcript [Seeking Alpha]
8/28
07:00 am
imab
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
High
Report
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
8/26
07:00 am
imab
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference